Skip to content

Study · Ex vivo tissue · 1990

4 results

Melanotropin receptors demonstrated in situ in human melanoma.

Tatro JB, Atkins M, Mier JW, Hardarson S, Wolfe H, Smith T, Entwistle ML, Reichlin S

The Journal of clinical investigation1 Jun 1990Cited by 54 (Europe PMC)

PMID2347915 (opens in a new tab)PMCIDPMC296647 (opens in a new tab)DOI10.1172/jci114642 (opens in a new tab)PepBankPUB-02347915
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabEx vivo tissueActivity measurement

    In melanoma specimens from 11 patients, specific [125I]NDP-MSH binding was high in 3, low in 5 and not detectable in 3.

    In plain wordsIn lab tests on melanoma specimens from 11 donors, NDP-MSH bound strongly in 3, weakly in 5 and not at all in 3.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableSpecific NDP-MSH binding in melanoma specimens
    Study

    humann = 11

    frozen surgical specimens of human melanoma
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In melanoma specimens from 11 patients, 3 showed high levels of specific binding, 5 showed low levels, and in 3 patients specific binding of [125I]NDP-MSH was not detectable.
    2 context sentences
    Summary · context
    We report here the use of an in situ binding technique to demonstrate specific MSH receptors in surgical specimens of human melanoma.
    Summary · context
    The distribution and binding properties of specific MSH binding sites were determined by autoradiography and image analysis after incubation of frozen tumor tissue sections with a biologically active, radiolabeled analogue of alpha-MSH, [125I]iodo-Nle4, D-Phe7-alpha-MSH ([125I]NDP-MSH).
  2. 02LabEx vivo tissueActivity measurement

    In one patient, high levels of specific MSH binding were found in all samples from several tumor areas and from tumors excised on three occasions.

    In plain wordsIn lab tests on tissue from one donor, NDP-MSH binding stayed high across all samples taken at different times.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableRepeatability of NDP-MSH binding within one patient
    Study

    humann = 1

    frozen surgical specimens of human melanoma
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In one patient, analysis of multiple intratumor samples and tumors excised on three separate occasions revealed high levels of specific MSH binding in all samples.
    2 context sentences
    Summary · context
    We report here the use of an in situ binding technique to demonstrate specific MSH receptors in surgical specimens of human melanoma.
    Summary · context
    The distribution and binding properties of specific MSH binding sites were determined by autoradiography and image analysis after incubation of frozen tumor tissue sections with a biologically active, radiolabeled analogue of alpha-MSH, [125I]iodo-Nle4, D-Phe7-alpha-MSH ([125I]NDP-MSH).
  3. 03LabEx vivo tissueActivity measurement

    In human melanoma specimens, specific MSH binding sites were present in melanoma cells but not in adjacent connective or inflammatory tissue.

    In plain wordsIn lab tests on human melanoma tissue, NDP-MSH bound to the melanoma cells but not to the tissue next to them.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    Not applicableCellular location of NDP-MSH binding sites
    Study

    humann: not reported in source

    frozen surgical specimens of human melanoma
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Specific MSH binding sites were present in melanoma cells, but not in adjacent connective or inflammatory tissues.
    2 context sentences
    Summary · context
    We report here the use of an in situ binding technique to demonstrate specific MSH receptors in surgical specimens of human melanoma.
    Summary · context
    The distribution and binding properties of specific MSH binding sites were determined by autoradiography and image analysis after incubation of frozen tumor tissue sections with a biologically active, radiolabeled analogue of alpha-MSH, [125I]iodo-Nle4, D-Phe7-alpha-MSH ([125I]NDP-MSH).

Studies that did not test the peptide alone1

In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan I (afamelanotide).

  1. 04LabNot a test of Melanotan I (afamelanotide) aloneEx vivo tissueActivity measurement

    In human melanoma specimens, melanotropins including alpha-MSH, NDP-MSH and ACTH inhibited [125I]NDP-MSH binding in a concentration-dependent manner, while somatostatin and substance P did not.

    In plain wordsIn lab tests on human melanoma tissue, melanotropins blocked labelled NDP-MSH binding in a dose-related way, but two unrelated peptides did not.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    DecreaseMelanotropin and unrelated peptide inhibition of [125I]NDP-MSH binding
    Study

    humann: not reported in source

    frozen surgical specimens of human melanoma
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    Melanotropins, including alpha-MSH, NDP-MSH, and ACTH, inhibited [125I]NDP-MSH binding in a concentration-dependent manner, whereas unrelated peptides (somatostatin and substance P) did not.
    2 context sentences
    Summary · context
    We report here the use of an in situ binding technique to demonstrate specific MSH receptors in surgical specimens of human melanoma.
    Summary · context
    The distribution and binding properties of specific MSH binding sites were determined by autoradiography and image analysis after incubation of frozen tumor tissue sections with a biologically active, radiolabeled analogue of alpha-MSH, [125I]iodo-Nle4, D-Phe7-alpha-MSH ([125I]NDP-MSH).

    In this study, Melanotan I (afamelanotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan I (afamelanotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.